The tricuspid annulus in amyloidosis with cardiac involvement: Detailed analysis from the three-dimensional speckle tracking echocardiographic MAGYAR-Path Study

Nemes, Attila; Rácz, Gergely; Kormányos, Árpád; Földeák, Dóra; Borbényi, Zita

doi:10.1016/j.ijcha.2022.101026

Cited by 3 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of note, more unexpected presentations of MR in CA, such as ruptured chordae, have also been published [ 35 ]. Moreover, CA is associated with distinct LV geometry changes, which in turn can also cause insufficient mitral valve closure [ 28 , 36 , 37 ]. Finally, left atrial enlargement represents a hallmark sign of restrictive cardiomyopathies, often leading to mitral valve annular dilatation and atrial functional MR [ 32 ].…”

Section: Mitral Regurgitationmentioning

confidence: 99%

“…Furthermore, our literature review yielded only two case reports on concomitant AV valve stenosis in CA (one AL and one Serum amyloid A amyloidosis) [ 47 , 48 ]. This low prevalence may partly be explained by the AV annulus dilatation, which is commonly observed in CA and counteracts possible stenotic processes [ 37 ].…”

Section: Mitral and Tricuspid Stenosismentioning

confidence: 99%

See 1 more Smart Citation

Cardiac Amyloidosis and Valvular Heart Disease

Duca,

Kronberger,

Willixhofer

et al. 2023

JCM

View full text Add to dashboard Cite

Growing interest has accrued in the co-existence of cardiac amyloidosis and valvular heart disease. Amyloid infiltration from either transthyretin (ATTR) or of light chain (AL) origin may affect any structure of the heart, including the valves. The recent literature has mainly focused on aortic stenosis and cardiac amyloidosis, improving our understanding of the epidemiology, diagnosis, treatment and prognosis of this dual pathology. Despite being of high clinical relevance, data on mitral/tricuspid regurgitation and cardiac amyloidosis are rather scarce and mostly limited to case reports and small cases series. It is the aim of this review article to summarize the current evidence of concomitant valvular heart disease and cardiac amyloidosis by including studies on epidemiology, diagnostic approaches, screening possibilities, therapeutic management, and prognostic implications.

show abstract

Section: Mitral Regurgitationmentioning

confidence: 99%

Section: Mitral and Tricuspid Stenosismentioning

confidence: 99%

Cardiac Amyloidosis and Valvular Heart Disease

Duca,

Kronberger,

Willixhofer

et al. 2023

JCM

View full text Add to dashboard Cite

show abstract

“…(35) Moreover, CA is associated with distinct LV geometry changes which in turn can also cause insufficient mitral valve closure. (28,36,37) Finally, left atrial enlargement represents a hallmark sign of restrictive cardiomyopathies, often leading to mitral valve annular dilatation and atrial functional MR. (32) Mixed etiologies may also occur. Thus, MR in the context of CA is indeed a rather complex disease, which is underlined by the fact that it can present as Carpentier classes I-III.…”

Section: Pathophysiological Aspectsmentioning

confidence: 99%

Cardiac Amyloidosis and Valvular Heart Disease

Duca,

Kronberger,

Willixhofer

et al. 2023

Preprint

View full text Add to dashboard Cite

Growing interest has accrued in the co-existence of cardiac amyloidosis and valvular heart disease. Amyloid infiltration from either transthyretin (ATTR) or light chain (AL) origin may affect any structure of the heart, including the valves. Recent literature has mainly focused on aortic stenosis and cardiac amyloidosis, improving our understanding of epidemiology, diagnosis, treatment and prognosis of this dual pathology. Even though of high clinical relevance, data on mitral/tricuspid regurgitation and cardiac amyloidosis is rather scarce and mostly limited to case reports and small cases series. It is the aim of this review article to summarize the current evidence of concomitant valvular heart disease and cardiac amyloidosis including epidemiology, diagnostic approaches, screening possibilities, therapeutic management, and prognostic implications.

show abstract